The FDA issued approval for Antares Pharma‘s (Ewing, New Jersey) needle-free injection device for use with Tev-Tropin brand human growth hormone (hGH) from Teva out of Petach Tikva, Israel. The device will be marketed under the name Tev-Tropin Tjet Injector system.
From the injector info page:
Reusable Needle-Free Injectors (Medi-Jector VISION®) deliver precise medication doses through high-speed, pressurized liquid penetration of the skin without a needle. These reusable, variable-dose devices are engineered to last for a minimum of two years and are designed for easy use, facilitating self-injection with a disposable plastic needle-free syringe to assure safety and efficacy. The associated disposable plastic needle-free syringe, offers high precision liquid medication delivery through an opening that is approximately half the diameter of a standard, 30-gauge needle and it is designed to last for approximately one week. Antares has sold the Medi-Jector VISION® for use in more than 30 countries to deliver either insulin or human growth hormone (“hGH”).
Press release: Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin® (Human Growth Hormone)
Product pages: Tev-Tropin; Antares Pharma injection devices…